Stay engaged in the latest updates on immuno-oncology in lung cancer, melanoma, and bladder cancer with this virtual grand rounds series. Each month you can participate in a new live webinar featuring an expert speaking on recent updates and key findings in immuno-oncology. You can access these webinars through your desktop computer, iPhone, iPad, and Android devices. Don’t miss out on this exciting series.
1.0 AMA PRA Category 1 Credit™
Benjamin Besse, MD, PhDGustave Roussy
Ronald de Wit, MD, PhDErasmus MC
Rotterdam, the Netherlands
Yohann Loriot, MD, PhDGustave Roussy
Dirk Schadendorf, MDUniversity Hospital Essen
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, melanoma, or bladder cancer.
After successful completion of this educational activity, participants should be able to:
- Examine the evidence for the role of biomarkers in immuno-oncology and how to apply them in clinical practice
- Select optimal immunotherapy approach for patients with cancer
- Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
- Develop strategies to recognize and manage adverse events resulting from the use of immunotherapies
This educational activity is supported by a grant from Merck Sharp and Dohme Corp.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.